European Patent Office

T 1760/11 ((-)-Omeprazole Mg/ASTRAZENECA) du 13.11.2012

Identifiant européen de la jurisprudence
ECLI:EP:BA:2012:T176011.20121113
Date de la décision
13 novembre 2012
Numéro de l'affaire
T 1760/11
Requête en révision de
-
Numéro de la demande
00108480.5
Langue de la procédure
Anglais
Distribution
Distribuées aux présidents des chambres de recours (C)
Téléchargement
Décision en anglais
Versions JO
Aucun lien JO trouvé
Résumés pour cette décision
-
Titre de la demande
Magnesium salt of the (-)-enantiomer of omeprazole and its use
Nom du demandeur
AstraZeneca AB
Nom de l'opposant
Hexal AG
Teva Pharmaceutical Industries
Mepha AG
STADA Arzneimittel AG
Pinewood Laboratories Limited
ETHYPHARM
Actavis Group hf.
Lupin Limited
Zentiva a.s.
Generics [UK] Limited
Ratiopharm GmbH
lA Pharma GmbH
Hexal Pharma GmbH
Hörnchen, Ulrich, Dr.
Chambre
3.3.01
Sommaire
-
Mots-clés
Admissibility of first partiality objection (yes), second (no)
Res judicata (no)
Main request, added matter (yes)
Auxiliary request 1, allowable
Added matter (no)
Sufficiency (yes), starting material retrievable from Chemical Abstracts
Novelty (yes), specific salt
Inventive step (yes), post-published evidence (yes), unexpected advantage
Referral to the Enlarged Board of Appeal (no)
Objection under Rule 106 EPC dismissed
Exergue
-

ORDER

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The case is remitted to the department of first instance with the order to maintain the patent with the following claims and a description to be adapted if necessary:

Claim(s): No. 1 to 13 of the auxiliary request 1 filed with the letter dated 6 April 2011 and received on 7 April 2011.

3. The request for referral to the Enlarged Board of Appeal of 15 November 2012 is rejected.

4. The objection of 16 November 2012 under Article 24(3) EPC is rejected as inadmissible.

5. The objection of 15 November 2012 under Rule 106 EPC is dismissed.